A Phase II Clinical Trial of Combination Nivolumab (Opdivo), Ipilimumab (Yervoy), and Taxane in Patients with Untreated Metastatic Non-Small Cell Lung Cancer (NSCLC) (The OPTIMAL Trial)
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Bristol-Myers Squibb Company
Start Date
August 9, 2018
End Date
July 31, 2023
Administered By
Duke Cancer Institute
Awarded By
Bristol-Myers Squibb Company
Start Date
August 9, 2018
End Date
July 31, 2023